» Articles » PMID: 20041693

Differential Phospholipid Binding of Alpha-synuclein Variants Implicated in Parkinson's Disease Revealed by Solution NMR Spectroscopy

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2010 Jan 1
PMID 20041693
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Three familial variants of the presynaptic protein alpha-synuclein (alphaS), A30P, E46K, and A53T, correlate with rare inherited Parkinson's disease (PD), while wild-type alphaS is implicated in sporadic PD. The classic manifestation of both familiar and sporadic PD is the formation of fibrillar structures of alphaS which accumulate as the main component in intraneuronal Lewy bodies. At presynaptic termini, the partitioning of alphaS between disordered cytosolic and membrane-bound states likely mediates its proposed role in regulation of reserve pools of synaptic vesicles. Previously, we reported on multiple distinct phospholipid binding modes of alphaS with slow binding kinetics. Here, we report the phospholipid binding properties of the disease variants, viewed by solution NMR in a residue-specific manner. Our results agree qualitatively with previous biophysical studies citing overall decreased lipid affinity for the A30P mutation, comparable affinity for A53T, and an increased level of binding of E46K, relative to wild-type alphaS. Additionally, our NMR results describe the distribution of lipid-bound states for alphaS: the population of the SL1 binding mode (residues 3-25 bound as a helix) is augmented by each of the disease variants, relative to wild-type alphaS. We propose that the SL1 binding mode, which anchors the N-terminus of alphaS in the lipoprotein complex while the hydrophobic NAC region remains dynamically disordered, is prone to intermolecular interactions which progress toward disease-associated oligomers and fibrils. The elevation of the SL1 binding mode, unchecked by a proportionate population of binding modes incorporating the full N-terminal domain, may well account for the increased toxicity of the A30P, E46K, and A53T disease variants of alphaS.

Citing Articles

A novel alpha-synuclein K58N missense variant in a patient with Parkinson's disease.

Al-Azzani M, Weber S, Ramalingam N, Ramon M, Shvachiy L, Mestre G medRxiv. 2025; .

PMID: 39990587 PMC: 11844588. DOI: 10.1101/2025.02.07.25321793.


Role of Lipids in the Pathogenesis of Parkinson's Disease.

Kamano S, Ozawa D, Ikenaka K, Nagai Y Int J Mol Sci. 2024; 25(16).

PMID: 39201619 PMC: 11354291. DOI: 10.3390/ijms25168935.


RXR nuclear receptor signaling modulates lipid metabolism and triggers lysosomal clearance of alpha-synuclein in neuronal models of synucleinopathy.

Tripathi A, Alnakhala H, Brontesi L, Selkoe D, Dettmer U Cell Mol Life Sci. 2024; 81(1):362.

PMID: 39162859 PMC: 11336128. DOI: 10.1007/s00018-024-05373-2.


VAMP2 regulates phase separation of α-synuclein.

Agarwal A, Chandran A, Raza F, Ungureanu I, Hilcenko C, Stott K Nat Cell Biol. 2024; 26(8):1296-1308.

PMID: 38951707 PMC: 11322000. DOI: 10.1038/s41556-024-01451-6.


Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis.

Burre J, Edwards R, Halliday G, Lang A, Lashuel H, Melki R Mov Disord. 2024; 39(10):1663-1678.

PMID: 38946200 PMC: 11808831. DOI: 10.1002/mds.29897.


References
1.
Ferreon A, Gambin Y, Lemke E, Deniz A . Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci U S A. 2009; 106(14):5645-50. PMC: 2667048. DOI: 10.1073/pnas.0809232106. View

2.
Zarranz J, Alegre J, Gomez-Esteban J, Lezcano E, Ros R, Ampuero I . The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004; 55(2):164-73. DOI: 10.1002/ana.10795. View

3.
Rospigliosi C, McClendon S, Schmid A, Ramlall T, Barre P, Lashuel H . E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J Mol Biol. 2009; 388(5):1022-32. PMC: 2719283. DOI: 10.1016/j.jmb.2009.03.065. View

4.
Conway K, Lee S, Rochet J, Ding T, Williamson R, Lansbury Jr P . Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000; 97(2):571-6. PMC: 15371. DOI: 10.1073/pnas.97.2.571. View

5.
Takamori S, Holt M, Stenius K, Lemke E, Gronborg M, Riedel D . Molecular anatomy of a trafficking organelle. Cell. 2006; 127(4):831-46. DOI: 10.1016/j.cell.2006.10.030. View